Form 8-K TherapeuticsMD, Inc. For: May 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
TherapeuticsMD (TXMD) PT Raised to $12 at Oppenheimer Following FDA Approval
May 30, 2018 12:26 PM EDTOppenheimer raised its price target on TherapeuticsMD (NASDAQ: TXMD) to $12.00 (from $10.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "TXMD announced FDA approval of Imvexxy (estradiol vaginal inserts) with a label supporting what we view as the best-in-class profile based on safety,... More
